Clinical trial · Observational
PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
NCT06322927CI-TRIAL-00110945iPREFERcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to participants when making treatment decisions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient Interview | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patient Interviews
- description
- Participants will be asked to take part in a 30-60 minute interview to understand their treatment preferences. Members of the research team will conduct this either in the clinic or over the phone, as per patient preference.
- interventionNames
- Other: Patient Interview
Primary outcomes (1)
- measure
- Patient Experience and Preference
- timeFrame
- 30-60 minutes
- description
- The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions.
Secondary outcomes (1)
- measure
- Treatment and Preference Differences
- timeFrame
- 30-60 minutes
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participants with confirmed MM (per standard disease specific diagnostic criteria) 2. Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories: 1. Subset 1- Participants must have received an oral anti-cancer therapy and a bi-specific antibody treatment. 2. Subset 2- Participants must have received an oral anti-cancer therapy and if they have not had a bi-specific antibody treatment, they must have received at least one IV therapy. 3. Aged 18 years of age or over 4. Able to provide informed consent 5. Able to communicate in English Exclusion Criteria: 1. Aged under 18 2. Unable to understand and communicate in the English language 3. Unable to provide written informed consent
References
Publications (1)
- DERIVEDPerry MB, Lochhead Devaraj R, Law K, Ashby F, Taylor S. iPREFER: Patients' Experiences and Preference of Treatment for Multiple Myeloma Following Multiple Lines of Treatment - A Qualitative Study. Patient Prefer Adherence. 2026 Apr 28;20:576524. doi: 10.2147/PPA.S576524. eCollection 2026. PMID 42080199